Close Menu

NEW YORK (GenomeWeb) – GenMark Diagnostics announced after the close of the market on Tuesday that it has applied to the US Food and Drug Administration for clearance of its ePlex Blood Culture Identification Gram-Negative (BCID-GN) and ePlex Blood Culture Identification Fungal Pathogen (BCID-FP) panels.

As a result, the firm has now completed submissions for all three of its ePlex molecular multiplex panels designed for the diagnosis and management of bloodstream infections that can lead to sepsis. The panels are being developed on GenMark's ePlex sample-to-answer system.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.

Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.

Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.

In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.